Dr Reddy's teams up with Auckland varsity

RELATED NEWS Dr Reddy's fixes ADS price at $16 Divis Laboratories making good moves Angel Broking sees Dr Reddy's Q2 net at Rs 191cr ALSO READ See latest News about Dr Reddys Labs See previous management interviews See what other Experts & Brokerages are saying about Dr Reddys Labs Dr Reddys Labs BSE | NSE 29/05/12 Are Mutual Funds betting on Dr Reddys Labs?

All the medicines in the pill are no longer covered by patents, so it will be cheap to produce and more affordable for people in developing countries. It is likely to cost only a few dollars a month in developing countries, according to a press release issued here today.

The investments

The Health Research Council of New Zealand has invested $350,000 to support the overall co-ordination of the trial and recruitment in New Zealand. Dr Reddy's will invest $7.5 million in developing the polypill and providing supplies for clinical trials globally.

In the study to be funded by a grant of $1.7 million from the Health Research Council of New Zealand, Dr Reddy's would provide the pills for the trial. The company has more than matched the investment in terms of pill development, manufacture and bio-equivalence testing.

Dr Reddy's Chief Operating Officer, Mr Satish Reddy, said 'There are two notable aspects of the collaboration. The first being the outstanding clinical development expertise and global credibility of Prof Rodgers and his team and second, the commitment to make the medicine affordable'.

The study is being led by Prof Anthony Rodgers of the University of Auckland's clinical trials research unit. Prof Rodgers is a recognized world leader in clinical trials and has been an advisor to the World Health Organisation (WHO). Prof Rodgers and other New Zealand researchers are also conducting a separate polypill trial in New Zealand with people at high risk of heart attack and stroke. It would involve 300 Maori and 300 non-Maoris.

Taken from Business Line

thehindubusinessline.in